Yahoo
Paris - Delayed Quote EUR

Sensorion SA (ALSEN.PA)

0.2520 -0.0050 (-1.95%)
As of 11:31:19 AM GMT+2. Market Open.
Reverse stock split
ALSEN.PA announces 1 for 50 split effective Sep. 15, 2026
Chart Range Bar
Loading chart for ALSEN.PA
  • Previous Close 0.2570
  • Open 0.2700
  • Bid --
  • Ask --
  • Day's Range 0.2520 - 0.2735
  • 52 Week Range 0.2220 - 0.8080
  • Volume 650,216
  • Avg. Volume 1,231,012
  • Market Cap (intraday) 129.864M
  • Beta (5Y Monthly) 0.42
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1000
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.14

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France. The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies. It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials. The company was incorporated in 2009 and is headquartered in Montpellier, France.

www.sensorion.com

63

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/3/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

ALSEN.PA
25.22%
CAC 40 (^FCHI)
1.39%

1-Year Return

ALSEN.PA
19.49%
CAC 40 (^FCHI)
7.04%

3-Year Return

ALSEN.PA
66.80%
CAC 40 (^FCHI)
13.24%

5-Year Return

ALSEN.PA
86.67%
CAC 40 (^FCHI)
23.52%

Analyst Insights

View More

Analyst Price Targets

0.70
1.14 Average
0.2520 Current
1.75 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
As of 9/1/2026
  • Market Cap

    137.08M

  • Enterprise Value

    90.90M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    925.39

  • Price/Book (mrq)

    3.08

  • Enterprise Value/Revenue

    1.30k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -26.12%

  • Return on Equity (ttm)

    -50.47%

  • Revenue (ttm)

    5.81M

  • Net Income Avi to Common (ttm)

    -29.43M

  • Diluted EPS (ttm)

    -0.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    47.46M

  • Total Debt/Equity (mrq)

    2.77%

  • Levered Free Cash Flow (ttm)

    -17.37M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: